Piflufolastat F 18
- Generic Name
- Piflufolastat F 18
- Brand Names
- Pylarify, Pylclari
- Drug Type
- Small Molecule
- Chemical Formula
- C18H23FN4O8
- CAS Number
- 1207181-29-0
- Unique Ingredient Identifier
- 3934EF02T7
- Background
Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases and recurrences. The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but...
- Indication
Piflufolastat F18 is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and for men with a suspected recurrence of prostate cancer based on elevated prostate-specific antigen (PSA) levels by t...
- Associated Conditions
- Prostate Cancer, Recurrent Prostate Cancer
- Associated Therapies
- -
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06099093
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Womens Hospital, Boston, Massachusetts, United States
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06085664
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05849298
- Locations
- 🇺🇸
Urology Clinic of North Texas, Dallas, Texas, United States
🇺🇸Univ of Texas Southwest Med Center Cardiovasc And Thoracic Surg, Dallas, Texas, United States
🇺🇸Urology Cancer Center PC, Omaha, Nebraska, United States
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05616650
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 350
- Registration Number
- NCT05588128
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05394259
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 130
- Registration Number
- NCT05155046
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 30
- Registration Number
- NCT05095519
- Locations
- 🇦🇺
St Vincent's Hospital, Fitzroy, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺The Royal Melbourne Hospital, Melbourne, Victoria, Australia
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Ashok Muthukrishnan
- Target Recruit Count
- 47
- Registration Number
- NCT04727736
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 13
- Registration Number
- NCT04573231
- Locations
- 🇺🇸
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.